当前位置:首页>产品中心>单抗/多抗>Anti-Rituximab Polyclonal Antibody|抗利妥昔单抗多克隆抗体(靶标:利妥昔单抗(抗CD20单抗))

Anti-Rituximab Polyclonal Antibody|抗利妥昔单抗多克隆抗体(靶标:利妥昔单抗(抗CD20单抗))

  • 货号:RB9TAY257024
  • 价格:面议
  • 点击:212

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA
特异性The product is specific for Rituximab. This antibody serves as an excellent positive control for Rituximab immunogenicity (ADA) assays.
靶标Rabbit polyclonal to Rituxan.
免疫原Rituximab
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
稳定性和储存The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号CAS: 174722-31-7
背景信息Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with certain autoimmune diseases and types of cancer, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, idiopathic thrombocytopenic purpura, and pemphigus vulgaris. Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death.
• Induction Immunosuppression in High-risk Kidney Transplant Recipients., PMID:27041548
• Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives., PMID:32520680
• Induction immunosuppressive therapies in renal transplantation., PMID:21258026
• Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production., PMID:18976291
• Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing., PMID:15896799
• [Biological treatment following renal transplantation]., PMID:21877601
• Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity., PMID:12632061
• Flow cytometric assay detecting cytotoxicity against human endogenous retrovirus antigens expressed on cultured multiple sclerosis cells., PMID:23656307
• Life-threatening hemolytic anemia due to an autoanti-Pr cold agglutinin: evidence that glycophorin A antibodies may induce lipid bilayer exposure and cation permeability independent of agglutination., PMID:19843291
备注For research use only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 425
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 612
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 673
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 552
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 482
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 481
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 217
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 455
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 516
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 506
Anti-Human CD42b/GP1BA Recombinant Antibody|抗人CD42b/GP1BA重组抗体(靶标:人血小板糖蛋白Ibα链/CD42b) 684
Anti-Human JMJD1C Polyclonal Antibody|抗人JMJD1C多克隆抗体(靶标:人Jumonji结构域含蛋白1C) 481
Anti-Human ITGB6 Polyclonal Antibody|抗人ITGB6多克隆抗体(靶标:人整合素β6亚基) 662
Anti-Mouse IL33 Recombinant Antibody |抗小鼠IL33重组抗体(靶标:小鼠白细胞介素33) 430
Anti-Mouse CD1d/CD1.1 Recombinant Antibody|抗小鼠CD1d/CD1.1重组抗体(靶标:小鼠CD1d分子) 606
Anti-Mouse α5β1 (ITGA5 & ITGB1) Recombinant Antibody|抗小鼠α5β1(ITGA5和ITGB1)重组抗体(靶标:小鼠整合素α5β1复合物) 624
Anti-Mouse VEGFA Recombinant Antibody|抗小鼠VEGFA重组抗体(靶标:小鼠血管内皮生长因子A) 347
总计 33037 个记录,共 1652 页,当前第 1652 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00